


**JaCVAM statement
on the Reduced Local Lymph Node Assay (rLLNA)
for skin sensitization assay**

At the meeting concerning the above method, held on 4 July 2012 at the National Institute of Health Sciences (NIHS), Tokyo, Japan, the members of the Japanese Center for the Validation of Alternative Methods (JaCVAM) Regulatory Acceptance Board unanimously endorsed the following statement:

The reduced Local Lymph Node Assay (rLLNA) can be used as a screening test to distinguish between sensitizer or non-sensitizer applied under proper conditions considering the possibility of false negative.

Following the review of the results of the ICCVAM (Interagency Coordinating Committee on the Validation of Alternative Methods, USA) Background Review Document, Evaluation Report, and OECD (Organisation for Economic Co-operation and Development) Test Guideline revised No. 429, it is concluded that the Reduced Local Lymph Node Assay (rLLNA) for skin sensitization assay is clearly beneficial.

The JaCVAM Regulatory Acceptance Board has been regularly kept informed of the progress of the study, and this endorsement is based on an assessment of various documents, including, in particular, the evaluation report prepared by the JaCVAM ad hoc peer review panel for skin sensitization assay.



Takemi Yoshida
Chairperson
JaCVAM Regulatory Acceptance Board



Akiyoshi Nishikawa
Chairperson
JaCVAM Steering Committee

20 January, 2013